Current Cardiology Reviews最新文献

{"title":"Identifying Biomarkers for Atherosclerosis via Gene Expression and Biological Networking.","authors":"Sangeeta Chhotaray, Soumya Jal","doi":"10.2174/011573403X340118241113025519","DOIUrl":"10.2174/011573403X340118241113025519","url":null,"abstract":"<p><strong>Introduction: </strong>Atherosclerosis is a chronic disease caused by the accumulation of lipids, inflammatory cells, and fibrous elements in arterial walls, leading to plaque formation and cardiovascular conditions like coronary artery disease, stroke, and peripheral arterial disease. Factors like hyperlipidemia, hypertension, smoking, and diabetes contribute to its development. Diagnosis relies on imaging and biomarkers, while management includes lifestyle modifications, pharmacotherapy, and surgical interventions. Computational biology is transforming biological knowledge into clinical practice by identifying biomarkers that can predict clinical outcomes. This involves omics data, predictive modeling, and data integration. Statistical analysis-based methods are also being developed to develop and integrate methods for screening, diagnosing, and prognosing atherosclerosis.</p><p><strong>Methodology: </strong>The present work aimed to uncover critical genes and pathways to enhance the understanding of the mechanism of atherosclerosis. GSE23746 was analyzed to find differentially expressed genes (DEGs) using 19 control samples and 76 atherosclerotic samples.</p><p><strong>Results: </strong>A total of 76 DEGs were identified. Analysed DEGs using Gene Ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) to generate enrichment datasets. A Protein- protein Interaction (PPI) network of DEGs was created utilizing the Search Tool for the Retrieval of Interacting Genes (STRING).</p><p><strong>Conclusion: </strong>Ten hub genes, namely EGR1, PTGS2, TNF, NFKBIA, CXCL8, TNFAIP3, CCL3, IL1B, PTPRC, and CD83, were found to be significantly linked to atherosclerosis. Furthermore, the metabolic pathway analysis through KEGG and STRING provides potential targets for therapeutic interventions through HUB genes to diagnose the illness at an early stage, which aids in the reduction of cardiovascular risk. From risk factor profiling to the discovery of novel biomarkers, several components such as phospholipids, ANGPTL3, LCAT, and the proteinencoded OCT-1 gene, play a vital role in crucial processes. These compounds are potential therapeutic targets for early diagnosis of atherosclerotic lesions and future novel biomarkers.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X340118"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Ibrahim Al-Sawalha, Abdel Qader Abu-Salih, Mohammad Al-Bdour, Rula Al Shimi, Mohammad Al-Slehat, Amjad Almansi, Suhel F Batarseh, Moneeb Al-Taj, Nebras Jaloudi","doi":"10.2174/011573403X353157250115105436","DOIUrl":"10.2174/011573403X353157250115105436","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic ischemic heart failure is a major global health issue despite advancements in therapy. Stem cell (SC) therapy has emerged as a potential treatment, but its effectiveness remains uncertain. This study aimed to systematically review and meta-analyze the current evidence on SC therapy's efficacy.</p><p><strong>Methods: </strong>We conducted a comprehensive literature search in PubMed, Embase, and Cochrane databases up to April 2024. We included randomized controlled trials (RCTs) with blinded designs, focusing on patients with heart failure with reduced ejection fraction (HFrEF) treated with mesenchymal stem cells compared to placebo or sham interventions via percutaneous endomyocardial catheter systems. Data extraction, performed independently by two authors, focused on safety and efficacy variables. The meta-analysis used a random-effects model, with sensitivity analyses to address study heterogeneity.</p><p><strong>Results: </strong>Twenty studies were included in the meta-analysis. Significant improvements were observed in the stem cell group for left ventricular end-systolic volume (LVESV) (pooled effect size -7.59, 95% CI [-12.28 to -2.89], P=0.002) and stress SPECT outcomes (pooled effect size - 5.33, 95% CI [-6.73 to -3.93], P<0.00001). Sensitivity analysis reduced heterogeneity in left ventricular end-diastolic function (LVEDF) (P=0.01, I²=54%) and revealed a significant benefit for stem cell therapy (pooled effect size -3.87, 95% CI [-6.77 to -0.97], P=0.009). No significant effects were observed for left ventricular ejection fraction (LVEF) or myocardial oxygen consumption (MVO2). Functional improvements in New York Heart Association (NYHA) classification were noted (OR=4.22, 95% CI (1.14-15.68), P=0.03), though no significant differences were found in safety outcomes, including major cardiovascular events, mortality, or rehospitalization rates.</p><p><strong>Conclusion: </strong>Transendocardial SC therapy shows promise in improving certain cardiac parameters, though its impact on LVEF and MVO2 remains inconclusive, indicating the need for further research.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X353157"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Wnt Pathways with Small Molecules as New Approach in Cardiovascular Disease.","authors":"Seyed Mehdi Mousavi, Fatemeh Jalali-Zefrei, Mohammad Shourmij, Shiva Tabaghi, Amirhesam Davari, Saeed Bahador Khalili, Soghra Farzipour, Arsalan Salari","doi":"10.2174/011573403X333038241023153349","DOIUrl":"10.2174/011573403X333038241023153349","url":null,"abstract":"<p><p>The increasing incidences of morbidity and mortality associated with cardiovascular diseases represent significant difficulties for clinical treatment and have a major impact on patient health. Wnt signaling pathways are highly conserved and are well known for their regulatory roles in embryonic development, tissue regeneration, and adult tissue homeostasis. Wnt signaling is classified into two distinct pathways: canonical Wnt/β-catenin signaling and noncanonical pathways, including planar cell polarity and Wnt/Ca²⁺ pathways. A growing body of experimental evidence suggests the involvement of both canonical and non-canonical Wnt signaling pathways in the development of cardiovascular diseases, including myocardial hypertrophy, arrhythmias, diabetic cardiomyopathy, arrhythmogenic cardiomyopathy, and myocardial infarction. Thus, to enhance patient quality of life, diagnosing and treating cardiac illnesses may require a thorough understanding of the molecular functions played by the Wnt pathway in these disorders. Many small-molecule inhibitors specifically target various components within the Wnt signaling pathways, such as Frizzled, Disheveled, Porcupine, and Tankyrase. This study aims to present an overview of the latest findings regarding the functions of Wnt signaling in human cardiac disorders and possible inhibitors of Wnt, which could lead to novel approaches for treating cardiac ailments.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X333038"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of Veno-arterial Extracorporeal Membrane Oxygenation (VA-ECMO) for Acute High Risk Pulmonary Embolism: A Systematic Review.","authors":"Rohit Munagala, Humail Patel, Pranav Sathe, Avneet Singh, Mangala Narasimhan","doi":"10.2174/011573403X339627241224085451","DOIUrl":"10.2174/011573403X339627241224085451","url":null,"abstract":"<p><strong>Introduction: </strong>Pulmonary embolism (PE) associated with hemodynamic compromise, termed high-risk or massive acute PE (MAPE), is associated with increased morbidity and mortality. Despite advancements in procedural techniques and an increase in the availability of advanced therapies, the outcomes associated with high-risk PE remain poor. Here, we review the literature surrounding the use of Veno-arterial Extracorporeal Membrane Oxygenation (VAECMO), primarily as a bridging therapy, in patients presenting with high-risk pulmonary embolism.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis utilizing PubMed/MEDLINE from database inception until March 2024. The terms \"high-risk PE\", \"massive PE\" and \"MAPE\" were paired with \"VA-ECMO\", \"bridge therapy\" and \"solo therapy\" along with related terms to find and analyze relevant studies. The primary outcome assessed was in-hospital mortality.</p><p><strong>Results: </strong>Most comparative studies involved assessing VA-ECMO's utility as solo therapy vs as a bridge to advanced therapy. Out of the data involving VA-ECMO as solo therapy, most showed definite survival benefit in subset of populations with VA-ECMO's role being varied by age and cardiac arrest presence. A portion of studies were notable for finding no difference in outcomes; however no major retrospective determined negative effect of VA-ECMO. In head-to-head studies as a bridge, studies from multiple centers highlighted VA-ECMO's role in stabilizing and improving survival in massive PE prior to systemic or catheter directed thrombolysis. Follow-up studies were limited, however one retrospective showed 30-day mortality of 31% and the 1-year mortality of 54% post PERT call. Follow-up echocardiograms performed on survivors between 30-365 days from Pulmonary Embolism Response Team (PERT) activation interestingly all had normal Right Ventricular (RV) size and function with mild to no tricuspid regurgitation.</p><p><strong>Conclusion: </strong>Most major literature supports the use of VA-ECMO as either solo therapy or a bridge to advanced therapy in MAPE with additional shock or cardiac arrest. However, further studies are needed to develop society guidelines for regular initiation in cases of MAPE.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":"21 4","pages":"e1573403X339627"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Bibliometric and Visualization Analysis of Metabolic Reprogramming in Cardiovascular Diseases: Trends, Key Contributors, and Future Directions from 2000 to 2024.","authors":"Xing Chen, Liu Lin Yang, Li Xiang Li, Yan Deng","doi":"10.2174/011573403X371021250109064231","DOIUrl":"10.2174/011573403X371021250109064231","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming is critical in cardiovascular disease (CVD) research, affecting a variety of diseases such as myocardial damage, coronary heart disease, and atherosclerosis, and has also emerged as a therapeutic target. This study conducts a bibliometric analysis of the past 24 years to identify trends and hotspots in CVD metabolism, aiming to guide future research and inform policy.</p><p><strong>Methods: </strong>This study analyzes publications from January 1, 2000, to October 10, 2024, using the Web of Science Core Collection database. Tools like CiteSpace, VOSviewer, and SCImago Graphica were used for co-authorship, keyword, citation, and journal visualizations. Dual-map overlays and annual publication trends were examined to uncover hotspots, trends, and the progression of metabolic reprogramming in CVD.</p><p><strong>Results: </strong>This study analyzed 765 articles and reviews from 66 countries. The USA had the most publications, with the University of Milan being the most productive institution. Després, JP's team in Italy, published the most papers. The International Journal of Molecular Sciences had the highest publication count, while Cardiovascular Diabetology had the greatest citation impact. Recent research has mainly focused on the role of immune cell substrate metabolism in CVD.</p><p><strong>Conclusion: </strong>This study reveals the development trend and research characteristics of CVD metabolic reprogramming over the past 24 years, from the early focus on disease risk factors to the recent exploration of the transformation of immune cell metabolism. In the future, targeting immune cell metabolism will drive CVD therapy forward.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":"21 4","pages":"e1573403X371021"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180361/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum Cortisol and Cardiovascular Disease Risk - A Potential Biomarker.","authors":"Wei Jet Oo, Chooi Ling Lim, Mun Hon Goh, Rhun Yian Koh","doi":"10.2174/011573403X328499241106064553","DOIUrl":"10.2174/011573403X328499241106064553","url":null,"abstract":"<p><p>Cardiovascular disease (CVD), the leading cause of death globally, poses a significant burden on the healthcare sector. Its association with stress and Cushing's Syndrome has driven cortisol, the 'stress hormone,' to be a potential candidate in determining CVD risk. Cortisol synthesis and release through the hypothalamic-pituitary-adrenal (HPA) axis are regulated by several hormones and receptors involved in the pathological cascade towards CVD. Evidence suggests that metabolic syndrome plays a major role in cortisol-mediated CVD risk. On the other hand, non-metabolic features are also implicated when the association between cortisol and CVD risk remains significant upon normalisation of metabolic parameters. Correspondingly, the treatment for hypercortisolism is often found effective in lowering CVD risk. Despite available evidence, several factors continue to hinder the clinical use of cortisol as a risk biomarker for CVD. This review provides an insight into the role of serum cortisol in CVD progression and risk, with emphasis on the mechanistic features and parameters.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X328499"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172220/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142926501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Effect of Virgin Rice Bran Oil (VRBO) on Doxorubicininduced Cardiotoxicity in Wistar Rats.","authors":"Suseela Prema, Rakesh Verma, Amritesh Nagarwal, Meenakshi Bharkatiya, Madhuri Baghel, Ladli Kishore, Pranay Wal, Amin Gasmi","doi":"10.2174/011573403X327970250108045235","DOIUrl":"10.2174/011573403X327970250108045235","url":null,"abstract":"<p><strong>Introduction: </strong>The usage of doxorubicin (DOX), an antineoplastic drug that is frequently used for the cure of cancer, is restricted to maximal doses due to its cardiac toxicity. Reactive oxygen species produced by DOX result in lipid peroxidation and organ failure, ultimately resulting in cardiomyopathy. Due to its high polyphenol content, virgin rice bran oil (VRBO) is a diet nutritional supplement with a strong antioxidant. This study aimed to assess the potential defense of VRBO against DOX-induced cardiotoxicity.</p><p><strong>Methods: </strong>VRBO and DOX injections were administered to thirty male Wistar rats for 42 days after being randomly assigned to five groups.</p><p><strong>Results: </strong>The study demonstrated the cardioprotective effects of VRBO against doxorubicin (DOX)-induced cardiotoxicity. VRBO (0.71 and 1.42 ml/kg) significantly improved the heart-tobody weight ratio, reduced elevated serum CK-MB and LDH levels by 18.4% and 52.7%, respectively, and increased HDL by 43.1%. ECG parameters also improved, with reductions in QT interval (19%), ST interval (28%), and QRS complex (15%). VRBO enhanced systolic blood pressure (up to 21%) and heart rate (7.1%). Antioxidant markers showed notable recovery, with MDA levels reduced by 66.1%, while GSH, SOD, and catalase levels increased by 129.4%, 158.2%, and 84.8%, respectively.</p><p><strong>Conclusion: </strong>A cardioprotective benefit was found at middle and higher VRBO dosages. In order to demonstrate the effectiveness of VRBO as a cardioprotective medication, further research on dosage response and bioavailability is required.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X327970"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143058233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Contemporary Review on Heart Failure with Preserved Ejection Fraction: Epidemiology, Diagnosis, and Management.","authors":"Mahek Shahid, Ramzi Ibrahim, Abdulbaril Olagunju, Martina Mookadam, Farouk Mookadam","doi":"10.2174/011573403X318646240909072055","DOIUrl":"10.2174/011573403X318646240909072055","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) includes almost half of heart failure cases typified by a specific clinical syndrome. Despite diagnostic and management advances, HFpEF still presents a diagnostic challenge and a paucity of therapies specifically aimed at enhancing survival and improving quality of life is still lacking. This review elucidates the diagnostic complexity of HFpEF, highlighting the use of both subjective and objective criteria within algorithmic frameworks. It also examines the significant impact of comorbidities on the progression of HFpEF. Additionally, we explore the latest evidence on targeting these comorbidities therapeutically, although the benefits to mortality are still limited.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X318646"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancements in Cardiac Catheterization Safety: Novel Radiation Protection Approaches Redefining Occupational Health.","authors":"Zahra Shaghaghi, Roozbeh Narimani Javid, Maryam Alvandi","doi":"10.2174/011573403X304828240819050538","DOIUrl":"10.2174/011573403X304828240819050538","url":null,"abstract":"<p><p>Radiation exposure poses a substantial occupational risk for healthcare professionals in the catheterization laboratory (cath lab). The escalating complexity and frequency of interventional procedures, such as cardiac catheterizations and percutaneous coronary interventions, underscore the need for innovative strategies to mitigate radiation exposure. While traditional measures like lead aprons, thyroid collars, and goggles have been pivotal in reducing radiation exposure, they have limitations, especially during prolonged and intricate procedures. Consequently, there is a growing demand for advanced radiation protection methods that prioritize safety without compromising procedural efficacy. Recent strides in radiation protection technology have given rise to novel shielding devices and zero-radiation approaches tailored for cath lab use. The novel shields leverage innovative materials and designs to achieve superior attenuation of both scattered and direct radiation. Their ergonomic and adjustable features also ensure optimal shielding coverage without impeding the operator's skill or workflow. Multiple studies have validated the effectiveness of these advanced radiation protection methods in diminishing occupational radiation exposure in the cath lab. Initial findings suggest a significant reduction in doses for operators and staff, potentially lowering the risk of radiation-induced health complications over the long term. This article provides a comprehensive review of the current landscape of radiation protection shields in the cath lab, emphasizing the efficacy and potential of these cuttingedge shielding technologies.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X304828"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142016652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship between Using Renin-Angiotensin System Inhibitors with Mortality of Atrial Fibrillation: A Systematic Review and Meta-Analysis.","authors":"Reza Faramarz Zadeh, Shahab Masoumi, Negar Jafari, Venus Shahabi Rabori, Saeid Heidari-Soureshjani","doi":"10.2174/011573403X326428240902114410","DOIUrl":"10.2174/011573403X326428240902114410","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AFib) is a highly prevalent cardiac arrhythmia associated with increased mortality in affected persons. Renin-angiotensin system inhibitors (RASIs) have been suggested as potential therapeutic agents for cardiovascular and renal diseases.</p><p><strong>Objectives: </strong>However, the relationship between RASIs and mortality in AFib patients remains uncertain. Therefore, the present study was designed and implemented for this purpose.</p><p><strong>Methods: </strong>We searched PubMed/MEDLINE, Embase, Web of Science (WOS), Cochrane Library, and Scopus databases for studies published until 12 February 2024 with relevant keywords. We included studies that reported mortality outcomes in AFib patients treated with RASIs and non-users. The data extraction and quality assessment processes were conducted, and subgroup analyses and sensitivity analyses were done. The data were analyzed by Stata 15 using statistical tests, such as Chi-square and I2 tests.</p><p><strong>Results: </strong>A total of 15 studies (2007-2024; n=2,178,565 patients) examined the association between RASI drugs and mortality of patients with AFib. The results indicated that compared to the control group, the odds of AFib mortality in the group receiving RASIs were equal to 0.81(95% CI: 0.71-0.92; P-value ≤0.001). The study results did not indicate publication bias (Pvalue= 0.733). During the meta-regression analysis, none of the study variables demonstrated a significant relationship with the observed heterogeneity (P-value > 0.20). Cumulative OR results showed that from 2022 onwards, there was enough evidence to confirm the relationship using RASIs with mortality of patients with AFib.</p><p><strong>Conclusion: </strong>Therefore, this meta-analysis suggests that the use of RASI drugs is associated with reduced AFib mortality. However, the authors emphasize the need for further high-quality studies and large-scale randomized clinical trials to validate these findings.</p>","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":"e1573403X326428"},"PeriodicalIF":2.4,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12060919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}